A REVIEW ON: GUILLAIN-BARRE SYNDROME

Background and purpose: Since Guillain-Barre Syndrome, and Strohl first described Guillain-Barre syndrome (GBS) in 1916, the syndrome has received significant attention in the literature.In order to identify prospective directions for further research, the author examines the history of studies on its pathophysiology and therapy.Results: The present International Guillain-Barre Syndrome research, involving 2000 patients, is the result of previous investigations that have shown the clinical spectrum of GBS since the early 1900s.The most common kind, (AIDP), was discovered in the 1950s and 1960s to be inflammatory in character.In the 1990s, two types of axons were identified: acute motorsensory neurotoxic neurotoxicity and severe motor axonal neuropathy.In the 1990s and early 2000s, antibodies against the bacteria Campylobacter jejuni glycans were found to react with glycolipids upon axonal membranes, resulting in these forms.Although the precise cause of Acute Inflammation Demyelinating Polyneuropathy is uncertain, the immune system's responses to the compact synaptic proteins P2 and P0, which cause experimental immune neuritis, suggest the importance of T cells.Corticosteroids were not found to be beneficial in randomized controlled studies conducted throughout the 1970s and 1980s.Experiments in the 1980s and 1990s demonstrated the advantages of intravenous immunoglobulin and plasma exchange, respectively.